D. Hilliard

发表

Multiple‐Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

D. Bloomfield, L. Bortel, O. Laterza, 2008, Clinical pharmacology and therapeutics.

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

L. V. Van Bortel, A. Bergman, J. Wagner, 2009, British journal of clinical pharmacology.

A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology.

Gregory T O'Donnell, M. Ferrer, B. Strulovici, 2007, Analytical biochemistry.

Effects of Etoricoxib and Comparator Nonsteroidal Anti‐Inflammatory Drugs on Urinary Sodium Excretion, Blood Pressure, and Other Renal Function Indicators in Elderly Subjects Consuming a Controlled Sodium Diet

B. Gertz, K. Lasseter, K. Gottesdiener, 2007, Journal of clinical pharmacology.

The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo.

P. Sterk, E. Bel, Z. Diamant, 1995, The Journal of allergy and clinical immunology.

Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist

G. O'neill, F. Liu, H. Greenberg, 2008, Clinical pharmacology and therapeutics.

Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D 2 Receptor

H. Greenberg, K. Metters, J. Wagner, 2007 .

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

W. Zeng, G. Herman, A. Bergman, 2005, Clinical pharmacology and therapeutics.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

J. Holst, W. Zeng, C. Deacon, 2006, The Journal of clinical endocrinology and metabolism.

Dipeptidyl Peptidase‐4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP‐1

J. Holst, B. Weiss, N. Thornberry, 2010, Clinical pharmacology and therapeutics.

Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects

W. Zeng, G. Herman, A. Bergman, 2006, Journal of clinical pharmacology.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

W. Zeng, G. Herman, A. Bergman, 2006, Clinical therapeutics.

Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects

O. Laterza, J. Wagner, J. Schwartz, 2008, Journal of clinical pharmacology.

Demonstration of specific COX‐2 inhibition by MK‐966 in humans with supratherapeutic doses

B. Gertz, E. Ehrich, A. van Hecken, 1999 .